On March 31, 2025 EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, reported the company will be presenting four poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Chicago, Illinois, from April 25-30, 2025, at the McCormick Place Convention Center (Press release, EpimAb Biotherapeutics, MAR 31, 2025, View Source [SID1234654053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The posters will feature: 1) Clinical results for EMB-01, an EGFR x cMet bispecific antibody, in colorectal cancer; 2) Preclinical data for EM1031, a novel KLK2 x CD3 bispecific T-cell engager; 3) Preclinical data for a novel LY6G6D x CD3 bispecific T-cell engager and 4) Preclinical data for a novel TCR based bispecific platform.

Details for the presentations are as follows:

EMB-01 EGFR x cMet bispecific antibody

Title: EMB-01, an EGFR/cMET bispecific antibody, in metastatic colorectal cancer: Results from an International Phase Ib/II study
Presentation number: CT168
Presentation Date: Tuesday, April 29, 2025
Presentation Time: 9:00AM – 12:00PM, local time (Location: Poster Section 49 Board Number 8)
EM1031 KLK2 x CD3 bispecific T-cell engager

Title: EM1031, a novel KLK2 x CD3 bispecific T-cell engager with highly effective efficacy in preclinical models
Presentation number: 3520
Presentation Date: Monday, April 28, 2025
Presentation Time: 2:00PM – 5:00PM, local time (Location: Poster Section 38 Board Number 28)
LY6G6D x CD3 bispecific T-cell engager

Title: A novel LY6G6D x CD3 bispecific T-cell engager demonstrates better tumor killing and minimal cytokine release than a benchmark molecule
Presentation number: 7317
Presentation Date: Wednesday, April 30, 2025
Presentation Time: 9:00AM – 12:00PM, local time (Location: Poster Section 40 Board Number 3)
TCR based bispecific platform

Title: Development of a novel TCR based bispecific platform for cancer therapy
Presentation number: 5446
Presentation Date: Tuesday, April 29, 2025
Presentation Time: 2:00PM – 5:00PM, local time (Location: Poster Section 15 Board Number 4)
"We are very pleased to share the promising efficacy signal of EMB-01 in Phase Ib/II clinical study for colorectal cancer as a poster presentation at the AACR (Free AACR Whitepaper) Annual Meeting, and 3 preclinical TCE assets and platform with differentiated efficacy and safety profile in solid tumors," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "The results of these studies are also providing validation of our TCE & bispecific technology platform in solid tumors, and we will further leverage this expertise to advance novel therapies for diseases with significant unmet need."